Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Marinella Clerico; Fabrizio Faggiano; Jaqueline Palace; George PA Rice; Mar Tintorè Subirana; Luca Durelli

doi:10.1002/14651858.CD005278.pub3

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Analysis 1.1

Comparison 1 Risk CDMS, Outcome 1 CHAMPS‐ETOMS‐BENEFIT metanalysis "per protocol" 1 year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Risk CDMS, Outcome 2 CHAMPS‐ETOMS‐BENEFIT metanalysis "likely" 1 year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Risk CDMS, Outcome 3 CHAMPS‐ETOMS‐BENEFIT metanalysis "worst" 1 year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Risk CDMS, Outcome 4 CHAMPS‐ETOMS‐BENEFIT metanalysis "best" 1 year.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Risk CDMS, Outcome 5 ETOMS‐BENEFIT metanalysis "per protocol" 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Risk CDMS, Outcome 6 ETOMS‐BENEFIT metanalysis "likely" 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Risk CDMS, Outcome 7 ETOMS‐BENEFIT metanalysis "worst" 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Risk CDMS, Outcome 8 ETOMS‐BENEFIT metanalysis "best" 2 years.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Serious adverse events frequency, Outcome 1 SAD, Metanalysis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Table 1. Treatment discontinuations

Observation period	Patients	CHAMPS (Treated)	CHAMPS (Placebo)	ETOMS (Treated)	ETOMS (Treated)	BENEFIT (Treated)	BENEFIT (Placebo)
year 1	Withdrawals	23	17	n.a	n.a	17	6
year 1	Early termination	28	21	n.a	n.a	n.a.	n.a.
year 2	Withdrawals	6	8	4	4	21	10
year 2	Early termination	55	45	n.a	n.a	n.a.	n.a.
year 3	Withdrawals	1	2	n.a	n.a	n.a.	n.a.
year 3	Early termination	n.a.	n.a.	n.a	n.a	n.a.	n.a.
n.a. = not available

Table 1. Treatment discontinuations

Ir a la tabla de la revisión

Comparison 1. Risk CDMS

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 CHAMPS‐ETOMS‐BENEFIT metanalysis "per protocol" 1 year Show forest plot	3	1110	Odds Ratio (M‐H, Fixed, 95% CI)	0.53 [0.40, 0.71]

2 CHAMPS‐ETOMS‐BENEFIT metanalysis "likely" 1 year Show forest plot	3	1154	Odds Ratio (M‐H, Fixed, 95% CI)	0.65 [0.50, 0.84]

3 CHAMPS‐ETOMS‐BENEFIT metanalysis "worst" 1 year Show forest plot	3	1154	Odds Ratio (M‐H, Fixed, 95% CI)	0.80 [0.61, 1.04]

4 CHAMPS‐ETOMS‐BENEFIT metanalysis "best" 1 year Show forest plot	3	1154	Odds Ratio (M‐H, Fixed, 95% CI)	0.43 [0.33, 0.56]

5 ETOMS‐BENEFIT metanalysis "per protocol" 2 years Show forest plot	2	768	Odds Ratio (M‐H, Fixed, 95% CI)	0.52 [0.38, 0.70]

6 ETOMS‐BENEFIT metanalysis "likely" 2 years Show forest plot	2	776	Odds Ratio (M‐H, Fixed, 95% CI)	0.56 [0.41, 0.74]

7 ETOMS‐BENEFIT metanalysis "worst" 2 years Show forest plot	2	776	Odds Ratio (M‐H, Fixed, 95% CI)	0.66 [0.49, 0.89]

8 ETOMS‐BENEFIT metanalysis "best" 2 years Show forest plot	2	776	Odds Ratio (M‐H, Fixed, 95% CI)	0.43 [0.32, 0.59]

Comparison 1. Risk CDMS

Ir a la tabla de la revisión

Comparison 2. Serious adverse events frequency

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 SAD, Metanalysis Show forest plot	3	1159	Odds Ratio (M‐H, Fixed, 95% CI)	0.83 [0.52, 1.34]

Comparison 2. Serious adverse events frequency

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet